MedTrace Logo

A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin

NCT00530946 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

To assess the changes in the trough Systolic Blood Pressure (SBP) and the percent changes in Low Density Lipoprotein-Cholesterol (LDL-C) from baseline at Week 8 in the treatment period

Conditions

Interventions

DRUG

Amlodipine 2.5mg/Atorvastatin 5mg

Single pill combination, dosed once daily for 8 weeks

DRUG

Amlodipine 2.5mg/Atorvastatin 10mg

Single pill combination, dosed once daily for 8 weeks

DRUG

Amlodipine 5mg/Atorvastatin 5mg

Single pill combination, dosed once daily for 8 weeks

DRUG

Amlodipine 5mg/Atorvastatin 10mg

Single pill combination, dosed once daily for 8 weeks

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00530946 on ClinicalTrials.gov